Goleta, CA, February 5, 2014 – The American Journal of Pathology announced in a press release that a peer-reviewed scientific article about Vascular BioSciences’ CAR peptide “A Novel Vascular Homing Peptide Strategy to Selectively Enhance Pulmonary Drug Efficacy in Pulmonary Arterial Hypertension” is the featured highlight article in the current February 2014 issue of The American Journal of Pathology, Volume 184, Number 2.
For each issue, The American Journal of Pathology highlights articles that are considered to be of significant interest to their readership. The press release, titled “New Research May Boost Drug Efficacy in Treating Pulmonary Arterial Hypertension,” highlights the potential of the CAR peptide as a therapeutic adjuvant for pulmonary arterial hypertension (PAH) when administered in combination with a variety of pulmonary medicines.
The featured article describes how CAR peptide was found to be effective in selectively enhancing the pulmonary vasodilation of fasudil, imatinib, sildenafil in a severe occlusive animal model of PAH. The results suggest a new paradigm in the treatment of PAH, using an i.v./sublingual tissue-penetrating homing peptide to selectively augment pulmonary vascular effects of nonselective drugs without the potentially problematic conjugation process. Along with this, CAR may have overcome a limitation of homing peptides through the discovery that sublingual administration might be superior to injection.
“It is exciting to learn that our research has been highlighted in the upcoming issue of The American Journal of Pathology,” commented Vascular BioSciences’ CEO and study co-author David Mann. “Pulmonary selective treatments have been a long-sought goal of PAH research. Our findings indicate that CAR peptide holds great promise as a novel means to deliver pulmonary selective therapies for PAH patients.”
The American Journal of Pathology has been published for over 60 years and is one of the most cited journals in the field of research pathology. The journal focuses on the cellular and molecular biology of disease, with an emphasis on human diseases and relevant experimental models.
To read the full press release, click on the following link: http://www.elsevier.com/about/press-releases/research-and-journals/new-research-may-boost-drug-efficacy-in-treating-pulmonary-arterial-hypertension
- View the Scientific Article plus Supplemental Figures
- Learn more about our Targeted Pharmaceuticals
- Learn how CAR Peptide works
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides disease solutions in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult-to-treat diseases.
For more information about VBS is available at www.vascularbiosciences.com/
For more information, please contact email@example.com